Table 1

Patient demographics and baseline disease characteristics (FAS)

Placebo
Q4W (n=60)
BKZ 16 mg Q4W (n=61)BKZ 64 mg Q4W (n=61)BKZ 160 mg Q4W (n=60)BKZ 320 mg Q4W (n=61)All patients
(n=303)
Age, years, mean (SD)39.7 (10.3)43.3 (12.6)40.4 (10.9)42.4 (13.1)45.0 (11.4)42.2 (11.8)
Sex (male), n (%)49 (81.7)53 (86.9)52 (85.2)52 (86.7)50 (82.0)256 (84.5)
Caucasian, n (%)60 (100)58 (95.1)60 (98.4)59 (98.3)61 (100)298 (98.3)
HLA-B27 positive, n (%)57 (95.0)51 (83.6)56 (91.8)52 (86.7)54 (88.5)270 (89.1)
Time since onset of first symptoms, years, mean (SD)14.1 (8.4)16.2 (10.6)12.4 (8.3)14.8 (10.3)15.3 (10.6)14.6 (9.7)
Time since diagnosis, years, mean (SD)6.6 (7.2)8.0 (9.4)7.3 (7.8)8.8 (9.2)8.8 (8.8)7.9 (8.5)
ASDAS, mean (SD)3.8 (0.9)3.9 (0.7)4.2 (0.8)3.9 (0.8)3.9 (0.7)3.9 (0.8)
hs-CRP, mg/L, mean (SD)17.6 (24.6)15.2 (17.7)23.5 (21.6)20.5 (19.3)18.4 (20.6)19.0 (20.9)
BASDAI, mean (SD)6.5 (1.4)6.7 (1.4)6.7 (1.3)6.3 (1.3)6.5 (1.6)6.5 (1.4)
BASFI, mean (SD)5.6 (2.0)5.9 (1.7)6.0 (1.8)5.6 (2.2)5.9 (2.0)5.8 (2.0)
BASMI, mean (SD)4.4 (1.6)4.8 (1.7)4.7 (1.7)4.6 (1.8)4.8 (1.8)4.7 (1.7)
Spinal pain score, mean (SD)7.0 (1.7)7.2 (1.9)7.4 (1.6)6.6 (2.0)7.3 (1.5)7.1 (1.7)
PGADA, mean (SD)7.0 (1.7)7.1 (1.5)7.3 (1.6)6.5 (1.8)7.1 (1.9)7.0 (1.7)
Previous TNF inhibitor therapy, n (%)7 (11.7)8 (13.1)7 (11.5)7 (11.7)5 (8.2)34 (11.2)
Current NSAID therapy, n (%)
 151 (85.0)53 (86.9)50 (82.0)54 (90.0)56 (91.8)264 (87.1)
 22 (3.3)3 (4.9)1 (1.6)1 (1.7)1 (1.6)8 (2.6)
Receiving csDMARDs, n (%)13 (21.7)9 (14.8)18 (29.5)18 (30.0)21 (34.4)79 (26.1)
  • ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; BKZ, bimekizumab; CRP, C reactive protein; csDMARD, conventional synthetic disease-modifying antirheumatic drug; HLA-B27, human leucocyte antigen-B27; NSAID, non-steroidal anti-inflammatory drug; PGADA, patient global assessment of disease activity; Q4W, every 4 weeks; TNF, tumour necrosis factor.